Search

CN-121975026-A - Cistanche tubulosa polysaccharide and application thereof

CN121975026ACN 121975026 ACN121975026 ACN 121975026ACN-121975026-A

Abstract

The invention discloses cistanche tubulosa polysaccharide and application thereof, and belongs to the technical field of biological medicines. The invention discloses a method for effectively promoting proliferation of RAW264.7 cells by CTN, CTBN and CTCA polysaccharides in a certain concentration range, and remarkably improving phagocytic activity of RAW264.7 cells to effectively play an immunoregulatory role and downregulate the secretion of NO by RAW264.7 cells. Can also effectively inhibit TNF-alpha, IL-1 beta and IL-6 inflammatory factors secreted by RAW264.7 cells after LPS stimulation to play the role of immunoregulation, and has wide application prospect.

Inventors

  • SHEN JING
  • YAO JUN
  • WANG YU
  • ZHENG DONGXUAN
  • CHANG JUNMIN
  • ZHANG HUI

Assignees

  • 新疆医科大学第一附属医院

Dates

Publication Date
20260505
Application Date
20240403

Claims (9)

  1. 1. A cistanche tubulosa polysaccharide is prepared from cistanche tubulosa powder by defatting, extracting with water, precipitating with ethanol, and purifying.
  2. 2. The cistanche tubulosa polysaccharide according to claim 1, wherein the cistanche tubulosa polysaccharide comprises three components of CTAN, CTBN and CTCA.
  3. 3. Cistanche tubulosa polysaccharide according to claim 2, characterized in that the nuclear magnetic analysis of CTAN is shown in figures 8-12.
  4. 4. Cistanche tubulosa polysaccharide according to claim 2, characterized in that the nuclear magnetic analysis of CTBN is shown in fig. 13-17.
  5. 5. The cistanche tubulosa polysaccharide according to claim 2, wherein the scanning electron microscope of CTCA is shown in fig. 20.
  6. 6. Use of cistanche tubulosa polysaccharide according to any of claims 1-5 for the preparation of a product for enhancing immunity.
  7. 7. Use of cistanche tubulosa polysaccharide according to any of claims 1-5 for the preparation of a medicament for increasing macrophage proliferation activity or phagocytic capacity.
  8. 8. Use of cistanche tubulosa polysaccharide according to any of claims 1-5 for the preparation of a medicament for reducing inflammatory factor levels.
  9. 9. The use of claim 8, wherein the inflammatory factors comprise TNF- α, IL-1β and IL-6.

Description

Cistanche tubulosa polysaccharide and application thereof Technical Field The invention relates to the technical field of biological medicine, in particular to cistanche tubulosa polysaccharide and application thereof. Background Cistanche tubulosa (CISTANCHE TUBULOSA (Schenk) Wight) is a perennial parasitic herb of cistanche genus of family Orobanchaceae. The dry fleshy stem with scaly leaves of cistanche tubulosa is warm in nature and sweet in taste, is a key herb for tonifying kidney and strengthening yang and relaxing bowel, and has the reputation of desert ginseng. Cistanche deserticola (recorded in 2005 edition of Chinese pharmacopoeia) is a genuine medicinal material. Cistanche deserticola is a rare traditional Chinese medicine for regulating the immune function of organisms, and can excite pituitary gland, adrenal cortex or has the action similar to that of adrenal cortex hormone. The cistanche tubulosa contains various bioactive components such as phenethyl alcohol glycoside, iridoid, polysaccharide, alkaloid and the like, and has the pharmacological effects of resisting oxidation, enhancing organism immunity, protecting liver, improving brain memory and the like. However, the research hot spot of cistanche tubulosa is mainly focused on phenylethanoid glycosides active ingredients, and the research on polysaccharide in cistanche tubulosa is less. In particular, there is no report of extracting and purifying cistanche tubulosa polysaccharide from cistanche tubulosa to obtain high purity cistanche tubulosa polysaccharide, and the structure of the cistanche tubulosa polysaccharide is not analyzed. Disclosure of Invention The invention aims to provide cistanche tubulosa polysaccharide and application thereof, so as to solve the problems in the prior art. In order to achieve the above object, the present invention provides the following solutions: the invention provides cistanche tubulosa polysaccharide which is obtained by degreasing cistanche tubulosa medicinal material powder, extracting with water, precipitating with ethanol and purifying. Preferably, the cistanche tubulosa polysaccharide comprises three components of CTAN, CTBN and CTCA. Preferably, the nuclear magnetic analysis of CTAN is shown in fig. 8-12, the FT-IR spectrum is shown in fig. 4 a, the total ion flow diagram is shown in fig. 5 a, the secondary mass spectrum is shown in fig. 6, and the structural unit is shown in fig. 22 a. Preferably, the nuclear magnetic analysis of the CTBN is shown in FIGS. 13-17, the FT-IR spectrum thereof is shown in FIG. 4b, the total ion flow chart thereof is shown in FIG. 5 b, the secondary mass spectrum thereof is shown in FIG. 7, and the structural unit thereof is shown in FIG. 22 b. Preferably, the scanning electron microscope of CTCA is shown in fig. 20. The invention also provides application of the cistanche tubulosa polysaccharide in preparing a product for improving immunity. The invention also provides application of the cistanche tubulosa polysaccharide in preparing medicines for improving macrophage proliferation activity or phagocytic capacity. The invention also provides application of the cistanche tubulosa polysaccharide in preparing medicines for reducing the level of inflammatory factors. Preferably, the inflammatory factors include TNF- α, IL-1β and IL-6. Based on the technical scheme, the invention has the following technical effects: the invention provides cistanche tubulosa polysaccharide and a preparation method thereof, wherein CTAN 210.49mg of purified polysaccharide is obtained, the yield is 35.68%, the yield is 49.39% of purified polysaccharide CTBN138.29mg, and the yield is 39.55% of purified polysaccharide CTCA174.04 mg. Experiments prove that the CTAN, CTBN and CTCA polysaccharides can obviously promote proliferation of RAW264.7 cells within a certain concentration range, and can obviously improve phagocytic activity of the RAW264.7 cells to effectively exert the immunoregulation function and down regulate the RAW264.7 cells to secrete NO. Can also effectively inhibit TNF-alpha, IL-1 beta and IL-6 inflammatory factors secreted by RAW264.7 cells after LPS stimulation to play the role of immunoregulation, and has wide application prospect. Drawings In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art. FIG. 1 shows the elution profile of polysaccharide from cistanche tubulosa in DEAE-650M column; FIG. 2 is an HPLC profile of neutral polysaccharides CTAN (a) and CTBN (b); FIG. 3 shows monosaccharide composition analysis of neutral polysaccharides CTAN (b) and CTBN (c), wherein (a) is a monosaccharide c